Douglas W. Sborov, MD, MS, provides a summary of the key details of the 54-year-old patient's medical history and multiple myeloma diagnosis.
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Treatment:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Douglas Sborov, MD.
Sborov discusses the case of FH, a 54-year-old woman who initially presented with back pain, fatigue, nausea, constipation, and occasional dizziness. Initial workup revealed profound anemia with hemoglobin of 7 g/dL, hypercalcemia with calcium of 11.3 mg/dL, creatinine of 1.5 mg/dL, albumin of 3.2 g/dL, β-2 microglobulin of 6 mg/L, and lactate dehydrogenase of 200 U/L. Bone marrow biopsy showed 22% monoclonal plasma cells. Serum protein electrophoresis showed an M spike of 5 g/dL. Involved κ light chains were 240 mg/L. Fluorescence in situ hybridization was negative for high-risk features. FH was diagnosed with Revised International Staging System (R-ISS) stage 2 IgG κ multiple myeloma and started on daratumumab, bortezomib, lenalidomide, and dexamethasone (DRVd) induction therapy, achieving a very good partial response (VGPR) before autologous stem cell transplant with melphalan 200 mg/m2.
Post transplant, FH retained a VGPR on lenalidomide maintenance. Sborov notes that although R-ISS stage 2 disease historically conferred a 5- to 7-year overall survival, available treatments such as chimeric antigen receptor T-cell therapy and bispecific antibodies are likely prolonging survival. Sustained minimal residual disease (MRD) negativity leads to better outcomes. While agreeing with the initial therapeutic approach, Sborov would have considered upfront autologous transplant even with low-level persistent disease, as the goal is deep MRD negativity in this young patient. However, balancing treatment intensity and secondary malignancy risk from early transplant exposure is warranted. Consolidation and doublet maintenance post transplant might have improved MRD negativity chances if they had been instituted. If a patient has a deep response, Sborov would continue lenalidomide over extended daratumumab exposure. He highlights debated issues such as optimal induction regimens and transplantation in the absence of survival data.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma
October 24th 2024During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.
Read More